Cupertino, CA, United States of America

Mark Fischer-Colbrie

This inventor holds 4 USPTO granted patents and 3 EPO patents. Top assignees: Hologic, Inc., Cytyc Corporation, Other. Active years: 2011-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Fischer-Colbrie. Retrieved from https://idiyas.com/inventor/mark-fischer-colbrie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2011-2016

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations by Mark Fischer-Colbrie

Introduction

Mark Fischer-Colbrie is an accomplished inventor based in Cupertino, CA. He holds a total of 4 patents that focus on the detection of oncofetal fibronectin, a significant biomarker in medical diagnostics. His work has contributed to advancements in health assessments and disease risk evaluations.

Latest Patents

Fischer-Colbrie's latest patents include methods and products for detecting oncofetal fibronectin indicating molecules in various samples. These methods involve treating samples with reagents and utilizing non-specific binders. His innovations also encompass imaging techniques for oncofetal fibronectin, which aid in testing subjects to ascertain health and disease status. Additionally, he has developed methods for detecting the presence of oncofetal fibronectin through immunoassays and mass spectrometry. These contributions are vital for selecting concepti and assessing the risk of developing diseases.

Career Highlights

Throughout his career, Mark Fischer-Colbrie has worked with notable companies such as Hologic, Inc. and Cytyc Corporation. His experience in these organizations has allowed him to refine his expertise in medical diagnostics and innovation.

Collaborations

Fischer-Colbrie has collaborated with esteemed colleagues, including Robert O. Hussa and Jerome P. LaPointe. These partnerships have further enhanced his contributions to the field of medical technology.

Conclusion

Mark Fischer-Colbrie's work in the detection of oncofetal fibronectin represents a significant advancement in medical diagnostics. His innovative methods and collaborations continue to impact the healthcare industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…